Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01189396
Other study ID # API-A006-CL-C
Secondary ID
Status Completed
Phase Phase 2
First received August 24, 2010
Last updated June 27, 2017
Start date July 2010
Est. completion date January 2011

Study information

Verified date June 2017
Source Amphastar Pharmaceuticals, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main objective is to evaluate the bronchodilatory efficacy, safety and pharmacokinetic profiles of A006 (Albuterol Dry Powder Inhaler (DPI)), in comparison with those of an active control, Proventil-HFA (Albuterol Metered Dose Inhaler (MDI)), and a Placebo DPI in escalating and cumulative-doses up to 1440 mcg, eight (8) times of the proposed clinical dose.


Recruitment information / eligibility

Status Completed
Enrollment 27
Est. completion date January 2011
Est. primary completion date December 2010
Accepts healthy volunteers No
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria:

- Body weight = 50 kg for men and = 45 kg for women, and BMI within the range of 18.5 - 30.0 kg/m2 inclusive;

- Sitting blood pressure = 135/90 mmHg;

- Demonstrating negative alcohol/drug screen tests;

- Demonstrating negative HIV, HBsAg and HCV-Ab screen tests;

- With mild-to-moderate persistent asthma for at least 6 months prior to Screening, and having used inhaled ß-agonist(s) for asthma control;

- Demonstrating a Mean Screening Baseline FEV1 at 50.0 - 85.0 % of predicted normal;

- Demonstrating a = 15.0% Airway Reversibility in FEV1 within 30(±5) min after inhaling 2 actuations of Proventil-HFA;

- Demonstrating Peak Inspiratory Flow Rate within 80-150 L/min;

- Demonstrating proficiency in the use of DPI and MDI after training;

- Females of child-bearing potential must be non-pregnant, non-lactating, and practicing a clinically acceptable form of birth control;

- Having properly consented to participate in the trial.

Exclusion Criteria:

- Smoking history of = 10 pack-years, or having smoked within 6 months prior to Screening;

- Upper respiratory tract infections within 2 wk, or lower respiratory tract infection within 4 wk;

- Asthma exacerbations that required emergency care or hospitalized treatment, within 4 wk prior;

- Any current or recent respiratory conditions that might significantly affect pharmacodynamic response to the study drugs, besides asthma;

- Concurrent clinically significant cardiovascular, hematological, renal, neurologic, hepatic, endocrine, psychiatric, malignancies, or other illnesses that could impact on the conduct, safety and evaluation of the study;

- Known intolerance or hypersensitivity to any of the ingredients of the A006 or Proventil-HFA;

- Use of prohibited drugs or failure to observe the drug washout restrictions;

- Having been on other clinical drug/device studies in the last 30 days;

- Having donated blood within the last 30 days prior to Screening.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
A006
Albuterol DPI with 180 mcg Albuterol/inhalation
Placebo DPI
Placebo DPI with 0 mcg Albuterol/inhalation
Proventil-HFA
Albuterol MDI with 90 mcg Albuterol/inhalation

Locations

Country Name City State
United States Amphastar Site 0025 Medford Oregon
United States Amphastar Site 0026 Portland Oregon
United States Amphastar Site 0032 San Antonio Texas
United States Amphastar Site 0034 Seattle Washington

Sponsors (1)

Lead Sponsor Collaborator
Amphastar Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

References & Publications (7)

Ahrens RC. The role of the MDI and DPI in pediatric patients: "Children are not just miniature adults". Respir Care. 2005 Oct;50(10):1323-8; discussion 1328-30. Review. — View Citation

Crapo RO, Morris AH, Clayton PD, Nixon CR. Lung volumes in healthy nonsmoking adults. Bull Eur Physiopathol Respir. 1982 May-Jun;18(3):419-25. — View Citation

Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis. 1981 Jun;123(6):659-64. — View Citation

Goldstein DA, Tan YK, Soldin SJ. Pharmacokinetics and absolute bioavailability of salbutamol in healthy adult volunteers. Eur J Clin Pharmacol. 1987;32(6):631-4. — View Citation

Hindle M, Newton DA, Chrystyn H. Dry powder inhalers are bioequivalent to metered-dose inhalers. A study using a new urinary albuterol (salbutamol) assay technique. Chest. 1995 Mar;107(3):629-33. — View Citation

Miller MR, Crapo R, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J; ATS/ERS Task Force. General considerations for lung function testing. Eur Respir J. 2005 Jul;26(1):153-61. Review. — View Citation

Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson DC, MacIntyre N, McKay R, Miller MR, Navajas D, Pedersen OF, Wanger J. Interpretative strategies for lung function tests. Eur Respir J. 2005 Nov;26(5):948-68. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Bronchodilatory efficacy after the escalating and cumulative-doses, up to 1,440 mcg. Area Under the Curve (AUC)0-t of percent change in Forced Expiratory Volume in 1 second (FEV1), which is defined as the area under curve of post-dose FEV1 percentage changes from the Pre-dose Baseline FEV1 (FEV10) versus time. Doses are at 0, 30, 60 and 90 min. -15 min predose, 15 min post dose 1, 2 and 3 and 15, 45, 90, 120, 180, 240, 360 min post dose 4
Secondary AUC0-t of change in FEV1 AUC of FEV1 volume post-dose changes (change in Volume) from the Pre-dose Baseline FEV1 (FEV10). Doses are at 0, 30, 60 and 90 min. -15, 15 min post 1, 2, and 3, and 15, 90, 120, 240, and 360min post dose 4
Secondary Time to onset Time to onset of bronchodilatory effect, determined by linear interpolation as the point where FEV1 % change first reaches = 12% from FEV10. 0 - 120 min
Secondary Peak Response The peak bronchodilator response, defined as the maximum post-dose FEV1 % change. Doses are at time 0, 30, 60, and 90 min. 15 min post dose 1, 2 and 3 and 15, 45, 90, 120, 180, 240, and 360 min post dose 4
Secondary Adverse Events The adverse drug events (ADE) that are observed with Proventil-HFA may be expected with the use of A006 Time 0, 15, 45, 75, 105, 150, 195, 130, 190, 250, 435 minutes post dose 1
Secondary Blood Analysis serum glucose and potassium analysis and PK analysis -15, 10, 25,40, 55, 70, 85, 95, 115, 145, 175, 210, 270, 330, 690 min post dose 1
Secondary Vital Signs and Electrocardiogram (ECG) vital signs, including pulse and blood pressure and 12-lead ECG -15, 5, 35, 65, 100, 155, 275, 455, 815 min post dose 1
See also
  Status Clinical Trial Phase
Completed NCT04624425 - Additional Effects of Segmental Breathing In Asthma N/A
Terminated NCT04410523 - Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma Phase 2
Active, not recruiting NCT03927820 - A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR) N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT03694158 - Investigating Dupilumab's Effect in Asthma by Genotype Phase 4
Terminated NCT04946318 - Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma Phase 2
Completed NCT04450108 - Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients N/A
Completed NCT03086460 - A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH) Phase 2
Completed NCT01160224 - Oral GW766944 (Oral CCR3 Antagonist) Phase 2
Completed NCT03186209 - Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE) Phase 3
Completed NCT02502734 - Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma Phase 3
Completed NCT01715844 - L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics Phase 1
Terminated NCT04993443 - First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036 Phase 1
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT06033833 - Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study Phase 2
Completed NCT03257995 - Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma. Phase 2
Completed NCT02212483 - Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients N/A
Recruiting NCT04872309 - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Withdrawn NCT01468805 - Childhood Asthma Reduction Study N/A
Recruiting NCT05145894 - Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device